Updated BEHOLD-1 results presented at ESMO 2026 show the investigational B7-H4-targeted antibody-drug conjugate mocertatug rezetecan produced a 62% confirmed objective response rate and median progression-free survival of 11.1 months at the dose selected for phase III. The data come from a single-arm phase Ib expansion, and no statistical significance is claimed.

What was announced

GSK plc (LSE:GSK) has presented updated data for mocertatug rezetecan, known as Mo-Rez, in patients with platinum-resistant ovarian cancer (PROC). The results were shown in a late-breaking oral session at the ESMO Congress 2026 in Madrid. The release was issued on 23 October 2026 in London.

Mo-Rez is an investigational antibody-drug conjugate (ADC) that targets B7-H4 and carries a topoisomerase inhibitor payload, with a drug-to-antibody ratio of 6. The data come from the phase Ib dose-expansion part of BEHOLD-1 (NCT06431594), a two-part, open-label phase I study. At the data cut-off, 136 PROC patients had been enrolled, and phase Ib patients had received one to three prior lines of therapy. Patients with endometrial cancer were also enrolled, but their data have not yet been reported.

The numbers

GSK (LSE:GSK) focused on the 5.8 mg/kg dose, which has been selected for phase III. In 45 patients treated at that dose, the confirmed objective response rate was 62% (28 of 45; 95% CI 46.5%–76.2%). The median duration of response was 12.2 months (95% CI 7.0–12.7), with follow-up beyond 13 months, and the median progression-free survival was 11.1 months (95% CI 8.3–13.9).

The release reports point estimates with confidence intervals only. Because BEHOLD-1 is a single-arm study without a comparator, it does not claim statistical significance, and the figures cannot be read as a head-to-head comparison with existing treatments.

On safety at 5.8 mg/kg, grade 3 or higher treatment-related adverse events occurred in 71% of patients (32 of 45), mostly haematologic. Treatment-related adverse events led to discontinuation in 2% (1 of 45), and interstitial lung disease or pneumonitis occurred in 2% (1 of 45). Across the whole PROC cohort, treatment-related adverse events led to dose interruptions in 51% of patients and dose reductions in 47%.

What the company and investigators said

Hesham Abdullah, Senior Vice President and Global Head of Oncology, R&D at GSK, said: "We have accelerated the phase III development programme across gynaecological cancers." He added that the results show "treatment responses and durability are maintained over time in many patients."

Vanda Salutari, a BEHOLD-1 study investigator at Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome, said: "The duration of response and progression-free survival observed in BEHOLD-1 are particularly encouraging."

Additional BEHOLD data were also presented at ESMO, including an exploratory biomarker analysis and the designs of the phase III studies.

Phase III programme and what to watch next

GSK said five pivotal phase III trials are now under way. They are BEHOLD-Ovarian01 in PROC, BEHOLD-Ovarian02 in platinum-sensitive ovarian cancer, BEHOLD-Ovarian03 in first-line maintenance for ovarian cancer without homologous recombination deficiency, BEHOLD-Endometrial01 in second-line advanced or recurrent endometrial cancer, and BEHOLD-Endometrial02 in first-line maintenance for mismatch repair proficient endometrial cancer.

GSK acquired exclusive worldwide rights to Mo-Rez from Hansoh Pharma, excluding mainland China, Hong Kong, Macau and Taiwan. The release mentions no regulatory designations for the drug.

Investors will look for the first endometrial cancer data from BEHOLD-1, further detail from the biomarker analysis, and enrolment progress in the phase III trials. The release does not give timelines for phase III readouts or regulatory filings. The high rate of grade 3 or higher haematologic events and the frequency of dose modifications are also likely to remain a focus as the programme moves into larger, randomised studies.